This key opinion leader (KOL) provides insights on the current treatment strategies for chronic spontaneous urticaria (CSU). The KOL discusses the effectiveness and safety of omalizumab as the recommended second-line treatment after antihistamine usage, while also highlighting the role of cyclosporine as an important off-label option. The KOL emphasizes the need for different drugs with various mechanisms of action, such as remibrutinib and anti-KIT drugs, to address the diverse needs of CSU patients. The discussion also covers the challenges in diagnosing CSU, the importance of patient compliance, and the potential impact of new therapies on the treatment landscape. The KOL underscores the significance of understanding the disease's pathological mechanism and the need for continuous treatment to achieve complete control of the disease.

This interview was conducted on 01 August, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.